Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELIEF trial of low-dose tamibarotene in HFpEF
jRCT2041260144Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Oct 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) comparing Tamibarotene with Placebo (2 arms). Primary endpoint: Serum NT-proBNP. Started Oct 2026; status: recruiting.
02
Drugs
tamibarotene
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on jRCT2041260144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041260144.